Study on the improvement of bioavailability and hepatoprotective effect of silybin-7-eicosanedioate long-acting injection based on prodrug technology
European Journal of Pharmaceutics and Biopharmaceutics · 2026
DOI: 10.1016/j.ejpb.2026.115144 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026. Verfasst von Junyi Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Inner Mongolia Medical University, No. 5, Xinhua Road, Hohhot, Inner Mongolia 010059, China. Electronic address: 19951974515@163.com. Hauptthemen laut MEDLINE: Silybin, Prodrugs, Liver, Silymarin. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Shanghai Professional Technology Service Platform on Cold Chain Equipment Performance and Energy Saving Testing Evaluation.
Abstract (Originalsprache)
Chronic hepatitis (CH) is a prevalent liver disease with poor clinical treatment efficacy due to the low bioavailability and short half-life of oral silybin (SLB) formulations. This study employed a long-chain fatty acid prodrug strategy to synthesize four SLB prodrugs (SLB-7-DDDA, SLB-7-TDDA, SLB-7-HDDA, SLB-7-ODDA), among which SLB-7-ODDA was identified as the optimal candidate owing to its lowest degradation rate (purity > 95%). SLB-7-ODDA long-acting suspension injection (SLB-7-ODDA-LAIS) was prepared via wet ball milling, which showed uniform particle size distribution, excellent redispersibility, and sustained-release properties in vitro. In vivo studies conducted in rats revealed that SLB-7-ODDA-LAIS exhibited a relative bioavailability of 613.60% compared with marketed SLB capsules, along with significantly prolonged half-life. It also exerted significant hepatoprotective effects against CCl4-induced CH by reducing serum transaminase levels, enhancing hepatic antioxidant capacity and alleviating liver fibrosis, and showed no significant muscle irritation. This formulation offers a novel long-acting therapeutic strategy for CH and a technical basis for enhancing the in vivo performance of low-bioavailability drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inner Mongolia Medical University, No. 5, Xinhua Road, Hohhot, Inner Mongolia 010059, China. Electronic address: 19951974515@163.com.
- Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China. Electronic address: weiruting0110@163.com.
- Inner Mongolia Medical University, No. 5, Xinhua Road, Hohhot, Inner Mongolia 010059, China. Electronic address: 15213951542@163.com.
- Inner Mongolia Medical University, No. 5, Xinhua Road, Hohhot, Inner Mongolia 010059, China. Electronic address: 17771564957@163.com.
- Shanghai Wei Er Lab, Shanghai 201707, China. Electronic address: cxmdyx01@163.com.
- Shanghai Wei Er Lab, Shanghai 201707, China. Electronic address: kuangyanting0430@163.com.
Förderung
- Shanghai Professional Technology Service Platform on Cold Chain Equipment Performance and Energy Saving Testing Evaluation
Zitieren
APA
Zhou, J., Wei, R., Li, B., Guo, B., Chen, X., Kuang, Y., Xu, Y., & Wu, X. (2026). Study on the improvement of bioavailability and hepatoprotective effect of silybin-7-eicosanedioate long-acting injection based on prodrug technology. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2026.115144
Vancouver
Zhou J, Wei R, Li B, Guo B, Chen X, Kuang Y, et al. Study on the improvement of bioavailability and hepatoprotective effect of silybin-7-eicosanedioate long-acting injection based on prodrug technology. European Journal of Pharmaceutics and Biopharmaceutics. 2026. doi:10.1016/j.ejpb.2026.115144
BibTeX
@article{Zhou2026,
author = {Zhou, Junyi and Wei, Ruting and Li, Baojuan and Guo, Bingjie and Chen, Xinmei and Kuang, Yanting and Xu, Youfa and Wu, Xin},
title = {Study on the improvement of bioavailability and hepatoprotective effect of silybin-7-eicosanedioate long-acting injection based on prodrug technology},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2026},
doi = {10.1016/j.ejpb.2026.115144}
}
EUVIMED